Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The World Health Organization has released new guidelines which, for the first time, recommend the use of an injectable form ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...

Share on Pinterest Lenacapavir is a twice-yearly injection to prevent HIV that could improve adherence rates compared to other PrEP medications. d3sign/Getty Images The WHO issued a global ...

PrEP treatments have been used in the United States to prevent HIV since 2012. These therapies generally involve daily oral medication (Truvada) or injections every two months (Apretude).